Vascular smooth muscle relaxation

Vascular smooth muscle relaxation refers to the reduction in contractile activity of the smooth muscle cells lining blood vessels, mainly arteries and arterioles. This process is essential for vasodilation, lowering vascular resistance, and regulating blood pressure. Molecular mechanisms include reduced intracellular calcium (by closing L-type calcium channels or enhancing calcium efflux/reuptake[1][5][7]), increased activity of myosin light chain phosphatase (MLCP[7][5]), and elevated signaling via cAMP or cGMP, often mediated by nitric oxide or vasodilator drugs[9][5]. Major therapeutic drug classes acting on these mechanisms include nitrates, β2-adrenoceptor agonists, calcium channel blockers, muscarinic agonists, potassium channel activators, and Rho-kinase inhibitors[8][9][2][4]. Because "vascular smooth muscle relaxation" is a process and not a specific molecular target (such as a receptor, ion channel, or enzyme), it would not be correct to list it as a canonical drug target. For structured information, individual molecules mediating this process—such as L-type calcium channel, Kv7 potassium channel, β2-adrenoceptor, muscarinic receptor, myosin light chain kinase, and others—are the actual drug targets[1][2][3][5][9].

Other names

VasorelaxationSmooth muscle relaxation (vascular)Vascular relaxation

Increase cGMP (via nitric oxide pathway)[5][9]; Increase cAMP (via β2-adrenoceptor stimulation)[9]; Inhibit L-type calcium channels[5]; Activate potassium channels for hyperpolarization[2]; Inhibit Rho-kinase pathway[4]; Stimulate myosin light chain phosphatase (MLCP) activity[7][5]